Butler Daniel J, Mozsary Christopher, Meydan Cem, Danko David, Foox Jonathan, Rosiene Joel, Shaiber Alon, Afshinnekoo Ebrahim, MacKay Matthew, Sedlazeck Fritz J, Ivanov Nikolay A, Sierra Maria, Pohle Diana, Zietz Michael, Gisladottir Undina, Ramlall Vijendra, Westover Craig D, Ryon Krista, Young Benjamin, Bhattacharya Chandrima, Ruggiero Phyllis, Langhorst Bradley W, Tanner Nathan, Gawrys Justyna, Meleshko Dmitry, Xu Dong, Steel Peter A D, Shemesh Amos J, Xiang Jenny, Thierry-Mieg Jean, Thierry-Mieg Danielle, Schwartz Robert E, Iftner Angelika, Bezdan Daniela, Sipley John, Cong Lin, Craney Arryn, Velu Priya, Melnick Ari M, Hajirasouliha Iman, Horner Stacy M, Iftner Thomas, Salvatore Mirella, Loda Massimo, Westblade Lars F, Cushing Melissa, Levy Shawn, Wu Shixiu, Tatonetti Nicholas, Imielinski Marcin, Rennert Hanna, Mason Christopher E
Department of Physiology and Biophysics, Weill Cornell Medicine, NY, USA.
The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, NY, USA.
bioRxiv. 2020 May 1:2020.04.20.048066. doi: 10.1101/2020.04.20.048066.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide, including >18,000 in New York City (NYC) alone. The sudden emergence of this pandemic has highlighted a pressing clinical need for rapid, scalable diagnostics that can detect infection, interrogate strain evolution, and identify novel patient biomarkers. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs, plus a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, bacterial, and viral profiling. We applied both technologies across 857 SARS-CoV-2 clinical specimens and 86 NYC subway samples, providing a broad molecular portrait of the COVID-19 NYC outbreak. Our results define new features of SARS-CoV-2 evolution, nominate a novel, NYC-enriched viral subclade, reveal specific host responses in interferon, ACE, hematological, and olfaction pathways, and examine risks associated with use of ACE inhibitors and angiotensin receptor blockers. Together, these findings have immediate applications to SARS-CoV-2 diagnostics, public health, and new therapeutic targets.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)已在全球造成数千人死亡,仅在纽约市(NYC)就有超过1.8万人死亡。这场大流行的突然出现凸显了对快速、可扩展诊断方法的迫切临床需求,这些方法能够检测感染、研究毒株进化并识别新的患者生物标志物。为应对这些挑战,我们设计了一种用于检测鼻咽/口咽拭子中SARS-CoV-2感染的快速(30分钟)比色测试(环介导等温扩增法),以及一个用于宿主、细菌和病毒分析的大规模鸟枪法宏转录组学平台(全RNA测序)。我们将这两种技术应用于857份SARS-CoV-2临床标本和86份纽约市地铁样本,提供了纽约市新冠疫情的广泛分子概况。我们的结果定义了SARS-CoV-2进化的新特征,确定了一个新的、在纽约市富集的病毒亚分支,揭示了干扰素、血管紧张素转换酶、血液学和嗅觉途径中的特定宿主反应,并研究了与使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂相关的风险。这些发现共同对SARS-CoV-2诊断、公共卫生和新的治疗靶点具有直接应用价值。